Disease |
Acute myeloid leukemia with myelodysplasia related changes (AML-MRC) is a subgroup of AML. It was introduced in 2008 by the WHO classification and updated in 2016 (Weinberg et al., 2015). A diagnosis of AML-MRC requires ≥ 20% blasts and additionally one of the following three criteria: history of myelodysplastic syndrome (MDS) or myelodysplastic/myeloproliferative neoplasm (MDS/MPN) MDS-related cytogenetic abnormalities or multilineage dysplasia (≥ 50% dysplastic cells in≥ two hematopoietic lineages) (Arber et al., 2016a). |
Etiology | There are various risk factors which can cause AML in general. These risk factors can be categorized as genetic disorders, physical and chemical exposure, radiation therapy and chemotherapy. Even though many people are exposed, to various degrees, to carcinogens, only a few cases may present with a known history of carcinogen exposure. Currently, it is not fully understood why some people develop AML and some do not (Estey and Döhner, 2006). Genetically, many researchers favor the "two-hit" hypothesis first proposed by Hartmut Beug (Beug et al., 1978), and later by Gary Gilliland. This hypothesis states that for transformation, a mutation in a kinase coding gene such as RAS, KIT or FLT3 has to occur together with a class II mutation targeting a transcription of nuclear factor such as NPM1, RUNX1 or CEBPA. Today, we know about a high variation of somatic mutations and chromosomal abnormalities characterizing different types of AML. AML-MRC is often associated with the following chromosomal abnormalities (Table 1) (Deschler et al., 2006; Weinberg et al., 2015). |
Epidemiology | If the WHO classification is strictly applied, 48% of all adult AML cases meet the AML-MRC criteria. It tends to affect more male and is a disease of the elderly with a median age of 68 years. Additionally, it is associated with a higher frequency of unfavorable cytogenetics and, consequently, a worse clinical outcome (Davis et al.,2013; Xu et al., 2014; Weinberg et al., 2009). AML-MRC occurs more often de novo then secondary to myelodysplasia (Vardiman and Reichard, 2015). |
Cytology | AML-MRC cases commonly present with multilineage dysplasia. This is validated best with peripheral blood smears or bone marrow smears for identifying myeloid and erythroid dysplasia and bone marrow biopsy for identifying megakaryocytic dysplasia (Falini et al., 2016). Following the WHO classification an AML-MRC presents with ≥ 50 % dysplastic cells in at least two hematopoietic lineages. The dysplastic features are not unique for AML-MRC, but can be also detected in other hematopoietic diseases, such as MDS (Wu et al., 2013). Dysplastic neutrophils may exhibit a nucleus-cytoplasm dysynchrony, hypogranulation and abnormal nuclear segmentation (pseudo-Pelger-Huët anomaly), e.g. bi-nucleated segments (Weinberg et al., 2015). As mentioned, dyserythropoesis and dysmegakaryopoesis are also commonly seen. Dyserythropoesis presents with odd erythroid precusors and sometimes ring sideroblasts, as well as multinuclearity, megaloblastoid changes and karyorrhexis. Dysmegakaryopoesis commonly shows hypolobulated micromegakaryocytes, non-lobulated nuclei in megakaryocytes of all sizes and multiple widely separated nuclei (Wakui et al., 2008). |
Other features | Immunophenotype: Because of the heterogeneity and commonly associated cytogenetic abnormalities AML-MRC has no specific immunophenotypic profile. However, the immunophenotype of blasts exhibits similar characteristics as seen in MDS (Ayar et al., 2014). Antigens associated with myeloid differentiation, such as MPO, CD33, CD13, CD64, CD14 and CD15 are seen in various degrees (van Dongen et al., 2012). MDS related AMLs with monocytic differentiation also show expression of CD45 and lack CD34 (Van Dongen et al., 2012). Additionally, the aberrant expression of CD10, CD56 and CD7 in blasts may be found (Weinberg et al., 2016). AML-MRC cases associated with monosomy 5 or 7 may show aberrant expression of TDT and CD7 (Font et al., 2006). |
Treatment | The therapy of AML-MRC is based on regular AML-therapy with a risk-adapted chemotherapy including induction chemotherapy ("7+3"; daunorubicine plus cytarabine) and postinduction therapy, such as high-dose cytarabine or in high-risk patients, allogeneic transplantation in first remission. Using regular assessments, lab studies including cytogenetics and molecular analyses, the patient can be assigned to a risk group and treatment and prognosis can be determined and the decision between curative chemotherapy/allogeneic stem cell transplantation, palliative chemotherapy and best supportive care can be made (Estey and Döhner, 2006). Chemotherapy can be separated into two main parts. First, the induction therapy with the attempt to reach complete remission. Second, the consolidation therapy to prolong the complete remission. If the patient displays characteristics of high risk AML, a hematopoietic stem cell transplantation (HSCT) must be considered (Kumar, 2011). As AML-MRC frequently fulfills the high-risk criteria such as: 3(q21q26) abnormalities, RPN1/MECOM (EVI1), del(5q), del(7q), t(6;9), other 11q23 abnormalities, 17p abnormalities, or complex aberrant karyotypes described as at least 3 unrelated abnormalities excluding cases with t(8;21), inv(16), and t(15;17), an allogeneic stem cell transplantation will be the post-induction therapy of first choice in most adults (Vardiman and Reichard, 2015). |
Prognosis | The myelodysplastic changes and MDS associated chromosomal abnormalities of AML-MRC are associated with a worse prognosis and lower rates of event-free survival and overall survival. However, it was shown that there is no difference in prognosis between patients with AML-MRC with a history of MDS and the remaining cases of AML-MRC (Weinberg et al., 2009; Arber et al., 2003). Besides, AML-MRC with the absence of cytogenetic abnormalities seem to have a better prognosis (Weinberg et al., 2009). Additionally, AML-MRC with NPM1 mutations and with or without cytogenetic abnormalities show a better prognosis (Haferlach et al., 2009). This was also shown for CEBPA mutations (Vardiman and Reichard, 2015). Therefore AML-MRC with NPM1 or CEBPA mutations are excluded from the AML-MRC category in the WHO classification 2016 (Arber et al., 2016). The prognosis of AML-MRC particularly in context of multilineage dysplasia remains controversial (Vardiman and Reichard, 2015). In patients who have undergone allogenic HSCT there is no prognostic difference in AML-MRC patients compared to AML not otherwise specified (AML-NOS) (Ikegawa et al., 2016). |
The 2016 revision to the World Health Organization classi fi cation of myeloid neoplasms and acute leukemia |
Arber DA, Orazi A, Hasserjian R, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW |
Blood 2016 May; 127(20): 2391-2406 |
PMID 27069254 |
|
Prognostic Impact of Acute Myeloid Leukemia Classification |
Arber DA, Stein AS, Carter NH, Carter NH, Ikle D, Forman SJ, Slovak ML |
American Journal of Clinical Pathology 2003 Nov; 119(5): 672-680 |
PMID 12760285 |
|
Granulocyte, monocyte and blast immunophenotype abnormalities in acute myeloid leukemia with myelodysplasia-related changes |
Ayar SP, Ravula S, Polski JM |
Annals of Clinical and Laboratory Science 2014 Winter; 44(1): 3-9 |
PMID 24695467 |
|
Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia |
Bibault JE, Figeac M, Hélevaut N, Rodriguez C, Quief S, Sebda S, Renneville A, Nibourel O, Rousselot P, Gruson B, Dombret H, Castaigne S, Preudhomme C |
Oncotarget 2015 Sep; 6(26): 22812-21 |
PMID 26078355 |
|
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia The Cancer Genome Atlas Research Network |
Cancer T, Atlas G |
The New England Journal of Medicine 2013 May; 368(22): 2059-74 |
PMID 23634996 |
|
The genetic basis of myelodysplasia and its clinical relevance The genetic basis of myelodysplasia and its clinical relevance |
Cazzola M, Porta MGD, Malcovati L |
Blood 2013 May; 122(25): 4021-4035 |
PMID 24136165 |
|
Pediatric acute myeloid leukemia as classified using 2008 WHO criteria: a single center experience |
Davis KL, Marina N, Arber DA, Ma L, Cherry A, Dahl GV, Heerema-McKenney A |
American Journal of Clinical Pathology 2013 Jun; 139(6): 818-25 |
PMID 23690127 |
|
Acute myeloid leukemia: Epidemiology and etiology |
Deschler B, Lübbert M |
Cancer 2006 Nov; 107(9): 2099-2107 |
PMID 17019734 |
|
Acute myeloid leukaemia |
Estey E, Döhner H |
Lancet 2006 Nov; 368: 1894-1907 |
PMID 17126723 |
|
Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1) |
Falini B, Macijewski K, Weiss T, Bacher U, Schnittger S, Kern W, Kohlmann A, Klein HU, Vignetti M, Piciocchi A, Fazi P, Martelli MP, Vitlae A, Pileri S, Miesner M, Santucci A, Haferlach C, Mandelli F, Haferlach T |
Blood 2010 May; 115(18): 3776-3786 |
PMID 20203266 |
|
Evaluation of CD7 and terminal deoxynucleotidyl transferase (TdT) expression in CD34+ myeloblasts from patients with myelodysplastic syndrome |
Font P, Subirá D, Mtnez-Chamorro C, Castan S, Arranz E, Ramiro S, Gil-Fernández JJ, López-Pacual J, Alonso A, Pérez-Sáenz MA, Alaez C, Renedo M, Blas C, Escudero A, Fdez-Rañada, J. M. |
Leukemia Research 206 Aug; 30(8): 957-963 |
PMID 16417922 |
|
AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features |
Haferlach C, Mecucci C, Schnittger S, Kohlmann A, Mancini M, Cuneo A, Testoni N, Rege-Cambrin G, Santucci A, Vignetti M, Fazi P, Martelli MP, Haferlach T, Falini B. |
Blood 2009 Oct; 114(14): 3024-3032 |
PMID 19429869 |
|
Structural and functional properties of platelet-derived growth factor and stem cell factor receptors |
Heldin CH, Lennartsson J |
Cold Spring Harbor Perspectives in Biology 2013 Aug; 5(8): a009100 |
PMID 23906712 |
|
Allogeneic hematopoietic stem cell transplant overcomes poor prognosis of acute myeloid leukemia with myelodysplasia-related changes |
Ikegawa S, Doki N, Kurosawa S, Yamaguchi T, Sakaguchi M, Harada K, Yamamoto K, Hino Y, Shingai N, Senoo Y, Watanabe K, Igarashi A, Njima Y, Kobayashi T, Kakihana K, Sakamaki H, Ohashi, K. |
Leukemia and Lymphoma 2015 Apr; 57(1), 76-80 |
PMID 26084204 |
|
Genetic abnormalities and challenges in the treatment of acute myeloid leukemia |
Kumar CC |
Genes & Cancer 2011 Feb; 2(2): 95-107 |
PMID 21779483 |
|
Detection of t(3;5) and NPM1/MLF1 rearrangement in an elderly patient with acute myeloid leukemia: Clinical and laboratory study with review of the literature |
Lim G, Choi JR, Kim MJ, Kim SY, Lee HJ, Suh JT, Yoon HJ, Lee S, Lee WI, Park, T. S. |
Cancer Genetics and Cytogenetics 2010 Jun, 199(2), 101-109 |
PMID 20471513 |
|
Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia |
Malcovati L, Papaemmanuil E, Ambaglio I, Elena C, Gallò A, Della Porta MG, Travaglino E, Pietra D, Pascutto C, Ubezio M, Bono E, Da Vià MC, Brisci A, Bruno F, Cremonesi L, Ferrari M, Boveri E, Invernizzi R, Campbell PJ, Cazzola M |
Blood 2014 Aug; 124(9): 1513-1521 |
PMID 24970933 |
|
Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history ofMDSor MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as 'AML not otherwise specified' (AML-NOS) or 'AML with myelodysplasia-related changes' (AML-MRC) |
Miesner M, Haferlach C, Bacher U, Weiss T, Macijewski K, Klein H, Dugas M, Kern W, Schnittger S, Haferlach T |
Blood 2010 Oct; 116(15): 2742-2751 |
PMID 20581309 |
|
Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis |
Pabst T, Eyholzer M, Fos J, Mueller BU |
British Journal of Cancer 2009 Apr; 100(8): 1343-1346 |
PMID 19277035 |
|
Current findings for recurring mutations in acute myeloid leukemia |
Takahashi S |
Journal of Hematology & Oncology 2011 Sep; 4(1): 36 |
PMID 21917154 |
|
EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes |
Van Dongen JJM, Lhermitte L, Böttcher S, Almeida J, Van der Velden VHJ, Flores-Montero J, Rawstron A, Asnafi V, Lécrevisse Q, Lucio P, Mejstrikova E, Szczepa?ski T, Kalina T, de Tute R, Brüggemann M, Sedek L, Cullen M, Langerak AW, Mendonça A, Macintyre E, Martin-Ayuso M, Hrusak O, Vidriales MB, Orfao A |
Leukemia 2012 Sep; 26(9): 1908-1975 |
PMID 22552007 |
|
Acute myeloid leukemia with myelodysplasia-related changes. |
Vardiman J and Reichard K |
American Journal of Clinical Pathology 2015 Jul; 144(1): 29-43. |
PMID 26071460 |
|
Diagnosis of acute myeloid leukemia according to the WHO classification in the Japan Adult Leukemia Study Group AML-97 protocol |
Wakui M, Kuriyama K, Miyazaki Y, Hata T, Taniwaki M, Ohtake S, Sakamaki H, Miyawaki S, NaoeT, Ohno R, Tomonaga M |
International Journal of Hematology 2008 Mar; 87(2): 144-151 |
PMID 27387988 |
|
Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system |
Weinberg OK, Seetharam M, Ren L, Seo K, Ma L, Merker JD, Zehnder JL, Arber DA |
Blood 2009 Feb; 113(922): 1906-1908 |
PMID 19131546 |
|
Characteristics of the four subtypes of myelodysplastic/myeloproliferative neoplasms |
Wu H, Bian S, Chu J, Zhong X, Sun H, Zhang B, Lu Z |
Experimental and Therapeutic Medicine 2013 May; 5(5): 1332-1338 |
PMID 23737874 |
|
Characteristics of acute myeloid leukemia with myelodysplasia-related changes: A retrospective analysis in a cohort of Chinese patients |
Xu XQ, Wang JM, Gao L, Qiu HY, Chen L, Jia L, HU XX, Yang JM, Ni X, Chen J, Lü SQ, Zhang WP, Song XM |
American Journal of Hematology 2014 Sep, 89(9), 874-881 |
PMID 24861848 |
|
Acute leukaemia and myelodysplastic syndromes with chromosomal rearrangement involving 11q23 locus , but not MLL gene, 1-6 |
Zuo W, Wang SA, Dinardo C, Yabe M, Li S, Medeiros LJ, Tang G |
Journal of Clincal Pathology 2016 Aug; jclinpath-2016-203831 |
PMID 27496968 |
|